Healthcare Industry News: subarachnoid hemorrhage
News Release - April 27, 2007
Hemedex Signs Distribution Agreement with Codman
CAMBRIDGE, Mass., April 27 (HSMN NewsFeed) -- Hemedex, Inc., a privately-held Cambridge, MA medical device company, announced today that it has reached an agreement with Codman & Shurtleff, Inc. to distribute the only minimally invasive device that can measure cerebral blood flow and cerebral tissue perfusion in absolute units, in real time.Cerebral tissue perfusion, the rate at which blood is replenished at the capillary level, is the primary factor in the transport of oxygen and nutrients to the brain. Adequate cerebral tissue perfusion is an essential requirement to maintain brain function.
The Hemedex QFlow 500(TM) Perfusion Probe is placed into targeted cerebral tissue where it responds rapidly to changes in cerebral perfusion, allowing clinicians to quickly individualize therapy. The probe is connected to the Bowman Perfusion Monitor® which calculates, stores and displays the perfusion data.
Clinical data suggests this technology may help doctors better identify and manage those patients at risk for complications from stroke, traumatic brain injury and subarachnoid hemorrhage due to decreased cerebral blood flow by providing continuous, real-time, soft-tissue perfusion measurements in absolute units.
"The Hemedex QFlow 500 probe has provided an important advance in our neuro monitoring capabilities and has become a highly valuable tool in our clinical decision making," according to Geoffrey Manley, M.D., PhD, Chief of Neurotrauma at the San Francisco General Hospital and Medical Center and Co- Director of the UCSF Brain and Spinal Injury Center (BASIC). "We now seek to use the Hemedex technology whenever we are treating a severe traumatic brain injury in our Neuro Intensive Care Unit."
"Codman is a world class company that will be an excellent partner to help establish the Hemedex cerebral blood flow monitor as an essential element of neurosurgery practice by helping surgeons and clinicians optimize clinical decision making," said H. Frederick Bowman, Ph.D., Hemedex Chairman and CEO.
About Codman
Codman & Shurtleff, Inc. develops and markets a wide range of diagnostic and therapeutic products for the treatment of central nervous system disorders. The company was founded in 1838 and has established a strong leadership position within the industry.
About Hemedex
Hemedex, founded in 2000, develops and manufactures devices that quantify blood perfusion at the capillary level for applications in a range of clinical care indications.
Source: Hemedex
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
